Home / Transcripts / Aarti Drugs Limited (524348) · February 4, 2026

Aarti Drugs Limited (524348) Earnings Call Transcript

February 4, 2026

BSE Limited IN Health Care Pharmaceuticals earnings 52 min

Earnings Call Speaker Segments

operator operator
#1

Good day, ladies and gentlemen, and welcome to the Q3 and nine months FY26 earnings conference call for RT Drug Ltd. Please note that all participants will remain in listen-only mode, and following the presentation's conclusion, you'll have a chance to ask questions. If you require help at any point during this call, please signal an operator by pressing Star then zero on your Touchstone phone. A brief disclaimer before we start: this call may include forward-looking statements regarding the company that rest on the beliefs, opinions and expectations of the company as of today's date. Such statements do not guarantee future performance and may involve risks and uncertainties that are hard to predict. I'll now turn the conference over to Mr. Adish Patil, COO and CFO of Aati Drugs Ltd. Thank you, and over to you, sir.

Ardish Patel executive
#2

Thanks, and good morning to everyone who holds a stake in our business. We’re glad you could join us for the RT drugs call covering Q3 and the 9 months of FY26 results. With me on the line is Mr. Harshit Chawla, Joint Managing Director.

Harit Shah executive
#3

Morning, everyone.

Ardish Patel executive
#4

Mr. Harid Shah, Full Time Director, and Mr. Vishwa Sawla, Managing Director of Pinnacle Life Sciences, are joined by her Investor Relations Advisor, sg. We hope you've had a chance to go through our financial results and investor presentation for the quarter and nine months ended 31st December 2025, which have been uploaded with the stock exchanges and are also available on our website. I'll start by laying out the key operating and business highlights for the period, after which we'll go through the financial performance. On the business front, it's important to flag that a number of factors weighed on how this quarter turned out. Utilization levels stayed low, which hit overall performance and operating leverage. First, softer antibiotic demand shrank the overall market pool, so less capacity was being used, and that created margin pressure. Second, we ran into shipment delays from China that disrupted supply chains and stretched out lead times, putting strain on production schedules and adding to cost pressures. Third, a one time voluntary shutdown was carried out at one of our plants for refurbishment ahead of the European audit, which temporarily held back production. Finally, the new greenfield facilities ran below optimal utilization since they are in the initial ramp up phase. That too weighed on profitability. Now, on the positive side, on a year on year basis, we saw 7% volume growth in the standalone business segment and a negative rate variance of around 5%.

Ardish Patel executive
#5

Overseas shipments—particularly formulations—stood out as a major engine of growth, helping keep the broader business steady and adding favorably to margins. Our wide-ranging product lineup keeps doing vital work when demand swings in specific categories. The FICA plant, which began operating on September 25th, has moved into its scale-up phase. It reached roughly 30% utilization during its first quarter of operation, and we anticipate lifting that to approximately 50% by March and April 2026, then higher still in the quarters that follow. Notably, right now the plant covers just 10 to 15% of our captive needs for key intermediates employed in our anti-diabetic portfolio, though down the road it will greatly strengthen supply reliability and lessen reliance on outside sourcing. Consistent with our backward integration approach, we look for full self-reliance on these supplies within the next couple of quarters. Our salicylic acid plant at Tarapur likewise hit a significant milestone, having now scaled output to around 300 tons per month. At present, though, utilization for this product across the December 25 quarter remained below expectations. The facility has delivered better operational stability on quality parameters and solid waste management, with additional technology improvements on the way.

Ardish Patel executive
#6

Looking at the business segments, our formulations segment demonstrated encouraging momentum in the quarter, especially in the export market. The growing share of formulations, with exports contributing more, is consistent with our strategy of shifting toward higher-value offerings. And it improves overall business quality. As new markets and products scale up, we anticipate formulations will take on an increasingly larger part in our growth. Regarding regulatory matters, certification and approval processes are advancing according to plan; audit observations are being reviewed, and inspections took place at one of our facilities as part of ongoing regulatory initiatives, including preparations for European approvals. This is part of a broader roadmap aimed at expanding our presence in regulated and semi-regulated markets. After multiple quarters of pricing pressure, we think the business has hit an inflection point, helped by stabilizing realization and strengthening volume momentum. January sales are showing an encouraging trend and giving us confidence in a more positive trajectory for the quarters ahead. Looking forward, our focus stays firmly on ramping up capacity, operational efficiency, and margin improvement, while keeping strict capital discipline and regulatory compliance. We remain committed to executing our growth projects efficiently and to building a stronger, more resilient platform for sustainable long-term growth.

Ardish Patel executive
#7

Let's move on to how we performed financially on a consolidated basis. In Q3FY26, revenue came in at rupees 602.9 crore, compared with rupees 557.1 crore in Q3FY25, which works out to 8% growth. Year on year, EBITDA was Rs 56.3 crores versus rupees 62.3 crores in Q3FY25, a decline of 10%. On a Royal Y basis, the EBITDA margin was 9.3%. PAT came to rupees 40.5 crores, compared to rupees 25.7 crores in Q3FY25, up 58% on a YY basis, which translates to a PAT margin of 6.7%. Over nine months, FY26 revenue was rupees 1846.6 crores, as against rupees 1713.4 crores in the nine months of FY25, reflecting 8% growth PY. EBITDA came in at rupees 215 crore versus rupees 196.9 crore in the nine months of FY25, up 9% YUI, with an EBITDA margin of 11.6%. PAT was 139.7 crore compared with 94 crores in Q3FY25, up 49% Y O Y, translating to a PAD margin of 7.6%. Turning to the standalone business, for Q3FY26 revenue stood at rupees five hundred and thirty crores, contributing 88% of consolidated revenue. Exports accounted for 37% of that revenue. Within the API business, the antibiotic Therapeutic category contributed 35.1%; antiprotozoal 19.8%; anti inflammatory 12.9%; anti diabetic 16.6%; antifungal.

Ardish Patel executive
#8

Formulation brought in 12.2%, and the other part added 3.5% to overall API sales for the formulation segment. For Q3FY 26, formulation revenue was rupees 76.6 Crore, which is up 58%. Exports made up 67% of that revenue. With that said, we'd now like to open the floor for questions. Thank you.

operator operator
#9

Thanks a lot. We're moving into the Q&A portion now. If you'd like to pose a question, just hit star and one on your touchstone phone. Should you want to take yourself out of the queue, press star and two — and we ask participants to use handsets when asking. Ladies and gentlemen, we'll pause briefly while the queue comes together. Anyone wanting to ask something can press star and one on their touchstone telephone. Our first question comes from Vishal at Systematics. Please go ahead.

Vishal Manchanda analyst
#10

Good morning, and thank you for the chance to ask. My question concerns the formulation bill. I’d just like to clarify whether, in the formulation business, the main aim is to produce every formulation of the existing APIs for which those large capacities exist, or whether we would also make other formulations beyond the APIs where we have traditionally been strong.

Ardish Patel executive
#11

Vishwa, do you want to take this question?

Vishwa Savla executive
#12

Yeah. Yeah, I’ll take that. So right now we’re doing both — we’re working on 4 formulations of APIs that RP Drugs manufactures in house. But we’re not limiting ourselves to that, especially with our pipeline. We’re putting more focus on niche categories in the oncology and cardio diabetic range. Wherever RP has an API, obviously that’s a priority. But we’re not restricting ourselves only to drugs where Artisans manufactures the API.

Vishal Manchanda analyst
#13

Right, so specifically for oncology, you'd need dedicated capacity, wouldn't you? So those would be set up separately, correct?

Vishwa Savla executive
#14

Yes, we do have a dedicated oncology manufacturing site in the U.S. that is fDA approved for formulation.

Vishal Manchanda analyst
#15

Okay, and what's the—so if you wanted to split the manufacturing capacity between oncology and non-oncology, say in terms of investment, how would you do that?

Vishwa Savla executive
#16

To start with, oncology hasn’t brought in revenue yet. We haven’t begun commercial sales on the oncology side so far, since those products remain at the pipeline and filing stage. Commercialization of the first product happens this quarter, in Q4. As for capacity, measured in absolute tablet terms, roughly 90% sits in the general plant. However, when you look at potential revenue across the next three years, around 40% of revenue could come from oncology.

Vishal Manchanda analyst
#17

And as far as the investment goes, would it follow that same split — the revenue split, or.

Vishwa Savla executive
#18

Yeah, that would be a bit higher, since we're also putting more money into oncology on the product development side. So the total investment would probably come to about 50% — 40 to 50% going to oncology.

Vishal Manchanda analyst
#19

And we'll mainly handle contract manufacturing on both of those fronts, or we'll sort of have. So we'll have the dossier zone across both of these. Both of these categories, and then partners.

Vishwa Savla executive
#20

Right, so we handle both. For the domestic market, we mostly do contract manufacturing; for international markets, we develop our products and dossiers and then out-license them. That means we hold the IP, and we partner with local companies on marketing and distribution.

Vishal Manchanda analyst
#21

Alright, alright. Just one more question about metformin. The backward integration capacity we're building for methylamines — will that also serve the gliptins, or is it only for metformin?

Vishwa Savla executive
#22

No, that one is specifically for metformin.

Vishal Manchanda analyst
#23

Right, got it. Do you have any sense of Metformin — specifically, what share of total global metformin capacity would India account for?

Vishwa Savla executive
#24

Sure, we still need to run the current analysis, but let's look at a couple of years ago. At that point, we accounted for roughly 12, 13% of Indian capacities. However, at this moment we've boosted our capacities over the last one year. So with that added capacity, it's probably climbed to upwards of 15%.

Vishal Manchanda analyst
#25

Right, right. And we've got 180 crores sitting in CWIP. Is that allocated to the oncology block, or—

Vishwa Savla executive
#26

Right, no, no. So it’ll be part of it. Part will be the oncology dose development. And part has to do with a big 25-ton boiler that’s going to come on stream during this quarter. It’s a cogent boiler, a big boiler. So it’ll generate power as well as steam. And it’s part of one of the greenfield projects.

Vishal Manchanda analyst
#27

Okay, and last thing — if you could put a number on the backward integration projects, so the methylamine backward integration projects plus all those other cost-saving investments you've made, at peak utilization, if we could use it fully at 100%, what savings would that produce in the numbers?

Vishwa Savla executive
#28

Okay, so I get that this is a bit hard. To take a firm stance, because once extra. Capacity enters the picture, pricing is certainly going to shift. That product's margins will move somewhat. Going forward now that a new player has entered. But it should certainly help us lift gross contribution even more. On top of that, it should also assist us in. Boosting sales for a couple of specialty. Chemicals, which already went up during this quarter too. And they'll rise further in the March. Quarter, and over the following couple of quarters we'll keep ramping up output at the CYCA facility. So on the whole, what we're looking for is a lift of, say, you know, no less than a couple of. Percent in gross contribution at the company level once it operates, once it operates at full scale. Like, if you take today's prices and don't factor in any volatility ahead. If you want an absolute figure, you can verify whether prices hold for raw material. And for end product prices. It's an extremely, extremely, extremely rough figure. Very. If it reaches full-scale potential? EBITDA could come in a bit above 50 crores.

Vishal Manchanda analyst
#29

Got it. Thanks so much.

operator operator
#30

Thanks. We'll take our next question from Resham Jain at VVD Asset Managers. Resham, please go ahead.

Resham Jain analyst
#31

Hi, good morning. So I have a few questions. So the first one is whether it's possible to quantify all the things which you mentioned in your opening remarks with respect to shutdown and some of the new facilities coming up. I assume there will be losses related to that. So if each of those items, if you can just quantify how much impact would be there in this quarter because of all these things. You see a couple of the greenfield projects put together, put together now we don't have any issues at the Saika facility like we had in Silicil equipment because Cyca Facility this is the first quarter of ramp up and we have already ramped up to 30% and it is going very smoothly as far as the ramp up is concerned. So both this included probably at the EBITDA level it could have created a drag of roughly eight or eight and a half crores. And at the PBT level probably it would be around some 14, 15 crores.

Vishwa Savla executive
#32

However, that’s going to shift before long at the Saika facility. It will change for the salicylic facility as well — step by step during this quarter and then in the June quarter. As for the other matter of lower production capacity utilization, I don’t have a precise figure, but what’s going on, what has gone on? You know, we’ve sold quite a bit out of the FG stock during this particular quarter. So if you look at the numbers, roughly 30 crores of sales came from existing stocks rather than from fresh production. And on account of that, we estimate the impact at approximately 1% on the gross margins. Because when we sell out of stock, you know, the inventory — the valuation of that inventory usually contains 80% raw material content and a 20% overhead component. So that 20% would come to 6 crores. So that has produced a drag in the gross margins that we see for the December quarter. So definitely there have been multiple factors. So taken all together, it has produced a drag in the parent company, the standalone business, which is the API, and the Spectrem company, whereas the formulation department — that division — has performed quite well in the December quarter. But the good part is in Jan.

Vishwa Savla executive
#33

Across both of those segments, we're seeing solid momentum in the business. So hopefully that trend has already turned around. And in the March quarter, we ought to see some positive numbers.

Resham Jain analyst
#34

So my takeaway is that 8 crore weighed on the EBITDA line — roughly 30-odd crores for the year, and it could be larger in the earlier quarters. What we might see next year isn't merely breakeven; as we progress through the quarters, it could well turn positive. So at the EBITDA level, the overall effect ought to be considerably more positive in FY27. Is that the right way to understand it?

Vishwa Savla executive
#35

Yeah, that’s definitely the case.

Resham Jain analyst
#36

Got it. On the second question, about capex this year — I believe you said last quarter that we'd spend close to 200 crores on capex this year, and that wraps up the total 600 crore capex we'd mapped out before. So what would capex be, say, in FY27, on top of what was already planned earlier?

Vishwa Savla executive
#37

So, yeah, what we’d mapped out earlier — apart from one project, we’re nearly finished with the rest. The project that got left out was the expansion of the Metformin facility to roughly 2,500 to 3,000 tons per month. That was our long-term strategy. But due to some land issues at the start, we ended up doing the brownfield expansion instead. So we’ve already reached about 1,450 to 1,500 tons per month. We’ll scale that up to 1,800 tons per month within the existing facility — 1,800 to 1,900 tons per month. On top of that, we’re seeing some positive signs on the line side, so that will happen as well. And the main idea is to forward integrate in Metformin. The first step is that we’re going for US FDA approval for Metformin. We’ve already prepared a US DMF, and we’re in the process of filing it. Then we’ll try to trigger the audit in the coming year and take it from there. So that should improve our regulated sales of Metformin, and it will definitely give a very good EBITDA margin from those markets. Plus, the plan would be for the US market — through Pinnacle, we might be.

Vishwa Savla executive
#38

We're also launching ANDA for the Metformin tablets. Forward integration for Metformin is on the cards. That was the one project left out of the initial plan. We'll take it up over the coming couple of years. And besides that, there's some expansion of cardiovascular products from our existing line. Plus we've seen some increased demand for our antifungal products. So we're expanding capacity for that. Plus we're thinking along the lines of doing some level of CDMO in the chlorosulfonation chemistry, where we're already stronger. We already do contract manufacturing for a few MNCs as far as a few second products are concerned. So we want to expand in that line as well. Plus the methylamine chemistry, which was newly introduced through the CYCA plant. We're looking at exploring the options of various derivatives that will be part of that chemistry itself. So it will help us. You know, there will be synergies in the further expansion. So that should help us reduce cost also, and plus get some value addition. So that is the overall plan for the coming years for the Capex. And plus we're identifying new molecules as far as API and other staking.

Vishwa Savla executive
#39

Segment is concerned that this process is also underway, and we'll make an announcement as soon as something is finalized. That said, I would still hold to the view that you can expect roughly 150 to 200 crores of CapEx. Over the next two years, each—every year, 150 to 200 crores of CapEx every year. Taking into account the formulation oncology expansion and all the ideas I just mentioned.

Resham Jain analyst
#40

Got it, that's very clear. And how much debt is currently on the books?

Vishwa Savla executive
#41

Total debt right now sits at approximately 540 crores at the console level. At the standard level, it comes to roughly 392 crores. And in both of those, in both divisions, the debt splits evenly between long term and short term. It's almost 50 point something percent for each.

Resham Jain analyst
#42

Alright, thanks a lot. Wishing you the best. Thanks.

operator operator
#43

Thanks. We’ll take the next question from Dhuanil Desai at Total Capital. Your line is open.

Dhwanil Desai analyst
#44

Morning, Radish. First off, you mentioned January looked encouraging and that we've reached the inflection point where the negative price variance is sort of winding down. Earlier, we were looking for something like 15% volume growth in H2. So are we seeing a similar trend, and should we expect that kind of volume and therefore value growth as we move into FY27? Also.

Vishwa Savla executive
#45

We can expect — the main reason being that the growth we anticipated in FY26 hasn’t materialized to that extent. Which means that growth is going to be pushed ahead into FY27. So probably we can expect around, you know, 12 to 15% volume growth in FY27, with both the projects going smoothly. The greenfield projects I’m talking about.

Dhwanil Desai analyst
#46

So is it reasonable to think that most of the volume growth is going to come from the new projects and the existing product basket? You know, on that side, we aren't really expecting much volume growth, or perhaps single-digit volume growth. Is that a fair way to see it?

Vishwa Savla executive
#47

Right, so the current product basket ought to deliver single-digit volume growth, though the primary engine for volumes will be the new projects — both the salicylic acid lines and the cycarb lines.

Dhwanil Desai analyst
#48

Moving to the gross margin side for the second question: even after we adjust for those 100 basis points tied to the inventory challenges, that figure still falls short of the 36, 37% mark we were aiming to reach. So how should we think about this margin trajectory as we head into FY27, especially since a lot of backward integration will also come into play? Chlorosulfonation, too, will kind of pick up the specialty portion of it. So how should we view that number going forward?

Vishwa Savla executive
#49

Yes. So for this specific quarter on the console basis, what we can observe is roughly around 37, 35.9. The main factor, as I mentioned, is that we have sold from inventory. So that has also had an impact on the gross. Contribution of around 1% is what we feel. That and another thing is the export. Content of the standalone business in December. Quarter was slightly lower and typically the. Export market has better selling prices. So when the export percentage is higher, the gross margin is automatically a bit higher. So penetrating more into the export market is also one of our very critical strategies. Along with that, pushing our existing product basket into the European markets, because we are already strong in those products, and we are in the process of getting. European upgrades for those products from our regular volume plants. So from there, if we supply to Europe markets, that will definitely add to gross margin backward integration. Definitely. Yes. As I was telling you, currently in December we were only able to achieve on 12 odd percent of backward integration. For the anti diabetic I'm talking about specifically. So that will go to, you know, almost 1900% in 2 3/4.

Vishwa Savla executive
#50

That should definitely help improve gross contribution too. And beyond that, the formulation business will have a positive effect on gross contribution, probably starting in the second and third year — it may not show up right away in 27, but once oncology begins flowing into sales, that should also definitely lift gross contribution.

Dhwanil Desai analyst
#51

Okay, so I’ll follow up on that. For standalone EPI in FY27, should we be looking at something like 35 or 36% gross margin, or should we put in a lower figure?

Vishwa Savla executive
#52

No, I'd say assuming a 36% gross margin is reasonable. Getting to a 36% gross margin isn't all that difficult.

Dhwanil Desai analyst
#53

And regarding that 36% being achievable — what assumptions are you basing that on for the calic acid plant to, you know, reach a stable state?

Ardish Patel executive
#54

That is a big assumption. Or maybe European supply recovering plays a role in that too, you know.

Vishwa Savla executive
#55

So overall, the first one is the regulated market sales, along with the sales pickup from our E22 plant — that's the USFDA plant — and the backward integration improvement in salicylic acid is definitely going to have a big impact on overall gross margin. Those are the main assumptions.

Dhwanil Desai analyst
#56

Understood. And for the final question: you mentioned that we ought to anticipate capex of 150 to 200 crore in each of the next two years, even though we have only just exited a heavy CAPEX phase in which plants are still ramping up, which means the benefits in gross margin and EBITDA have not yet materialized. So why wouldn't we prefer to first stabilize and reach a solid operational efficiency level before undertaking capex, instead of moving into new projects where we would again keep pressuring our margins?

Vishwa Savla executive
#57

That analysis is spot on. There are a couple of factors behind it. First, the CYCA plant is running very smoothly. Our scale-up there has gone very smoothly, so we haven't run into any issues. On top of that, consumption from that plant is mainly captive — more than 50% is captive. So that project's scale-up will happen very quickly. We're therefore talking more in terms of 24 months, and the Saika results will begin arriving in six months itself. So within six months we'll come to know whether one of the greenfield capex projects is fully operationalized or not. That gives us a comforting factor after six months, and on salicylic acid we are almost at, meaning toward the end of, the improvement. And one more thing: 150 to 200 crores of that will also go toward oncology dossier development. So that matters too, because they already have an oncology approved foundation plant, a USFD approved plant, in Buddhi. So we want to capitalize on that. Plus we received European approvals for our OSD facility in Buddhist. So we also want to capitalize on that by having more doses on regular therapies for formulation.

Vishwa Savla executive
#58

On top of that, this figure will cover maintenance capex as well as the incremental expansion we carry out — our brownfield expansion will be included too. Beyond that, we're putting some capex into that solar power plant and into certain energy-related upgrades. That's our intention, so those items will be accounted for within this capex as well.

Dhwanil Desai analyst
#59

That's very clear. Thanks, and best of luck to all of you.

Vishwa Savla executive
#60

Thanks.

operator operator
#61

Thanks. Our following question comes from Yash Doshi at Unifi Capital Private Limited. The line is yours — please proceed.

Yash Doshi analyst
#62

Thanks. Can you hear me? Good. On that sacred asset line — if I recall correctly, last time we mentioned hitting roughly 800 metric tons a month, and we also brought up Chinese dumping. So, has that situation settled down, or is it — they're still — the dumping is continuing and relations have come. Yeah. Could you address the silic selling prices string?

Vishwa Savla executive
#63

Right. So Chinese dumping continues, but thanks to the rising dollar rate, our realizations are a bit better than what we saw last quarter. Even so, we're also working on applying the NTW duty starting at the beginning of next year against imports from China, and that will take somewhere between six and eight months — nine months, whatever time it takes after April, since as of right now we aren't eligible. So perhaps from April we'll be eligible to apply for NTWT as well. Let's hope so, and on the operational front we're putting in the effort. We're boosting our overall efficiency so that, you know, we come out of this break-even for next year.

Yash Doshi analyst
#64

Yeah, sorry, just to confirm: the cyclic acid line and the cycle plan together reported an EBITDA loss of 8.5 crores this quarter. Or is that 8.5 crores for a single plan? It's combined — combined. Okay. And about next year, if you look at EBITDA margins like this quarter, given the multiple headwinds, we reported nine for him; for next year at steady state, what will the EBITDA margin be around?

Vishwa Savla executive
#65

First off, at the start, our goal is to reach that 12 to 13% target, since at present it’s been pushed down considerably beneath that level. At the moment it stands at roughly 9.3. Yet in the prior quarter, in September, it came in at about 12.9%. So we’ll get to that 12 to 13% first, and after that the ideal steady-state margins, once everything begins running smoothly, ought to land somewhere in the 14 to 15% range.

Yash Doshi analyst
#66

Okay. And regarding the psychop line, initially at Next we're aiming for 50%. I believe the Q4 exit rate will be near that. So what's our target for next year?

Vishwa Savla executive
#67

So in Q1, right away we managed to reach roughly 30 utilization. For this quarter—the March quarter—our plan is to ramp that up to about 50% utilization. After that, in the following quarter, we're aiming for 75% utilization of the facility. The ramp-up ought to move quite quickly, so hopefully inside 12 months we should be nearly at 80 to 90%. The same applies to the sacrylic acid plant. For next year, our target is approximately 800,000 metric tons.

Yash Doshi analyst
#68

Right. So with salicylic acid, we're moving a bit slowly. There have been quite a few changes. So what happened? The story goes like this. We started up the plant almost in April. 24, and in January 25. We saw.

Vishwa Savla executive
#69

Apologies. So roughly a year ago, we observed that the specifications for salicylic acid had shifted considerably compared with when we first commissioned the plant. That meant we also had to address those quality parameters, so we made some slight adjustments to our processes. At present, what we're seeing — and here I'm referring to the industry and our competitors — is that the process, the physical chemistry of the organic chemistry, has stayed the same, though the physical chemistry side is somewhat different. New technology is arriving for salicylic acid, and we're looking into that as well so we can adopt it at our plants. That index matters to us if we're going to stay competitive going forward. So that's the sole reason I say we're still moving somewhat slowly on salicylic acid — but within 12 months we should probably aim to hit that mark of a thousand tons per month. That ought to be our target. At the same time, we're keeping a cautious eye on the new technologies coming through, which haven't been adopted yet but are being discussed for adoption at plant scale. So we're exploring that too.

Yash Doshi analyst
#70

Alright, got it. Yeah, that comes from me. Best of luck.

Vishwa Savla executive
#71

Thanks.

operator operator
#72

Thanks. We now have a question from Aditya at Sovilo Investments, who is on the line. Go right ahead.

Aditya Ravindran analyst
#73

Appreciate the chance to speak. I'd like to get a handle on, you know, the API pricing — a few quarters back there was talk that we might have hit the bottom there. But it seems like, you know, dumping is continuing, and there's been pressure on prices as well. So what sort of trajectory are we looking at, particularly on the API side?

Vishwa Savla executive
#74

So here's what we've seen: the overall rate, the negative rate variance, in the December quarter compared with September 25th — that's quarter on quarter — comes to roughly 2% to 2.5%. That said, it's mainly — not mainly, the whole reason for it is the antibiotic segment; the other segments, honestly, in a few of those other segments we've actually seen positive growth in prices as well. So it's product specific. We'll still hold to the position that prices have stabilized from September onward. There are just some product specific variations, a little bit. But more or less, prices have already stabilized. So from this point we don't see any reduction in prices.

Aditya Ravindran analyst
#75

All right. So just on the recent news — I'm only asking to see whether this touches us at all. Recently the government set an MIP for penicillin, correct? So would that carry any sort of impact on our input costs?

Vishwa Savla executive
#76

No. Not at this time. At present, that segment isn't something we handle. Still, the mip concept is one we're looking to test in a handful of situations, since that should help us secure improved realizations for our — for the goods we offer as import facilities.

Aditya Ravindran analyst
#77

Got it. All right. Thanks. That's all from me.

Vishwa Savla executive
#78

Thanks.

operator operator
#79

Thanks. Our next question comes from Sashi Ranjan, calling in from Sashi Ranjan Hospital Hospitality Private Limited. The line is yours — please go ahead.

Shashi Ranjan analyst
#80

Good morning, and thanks for having me. I’d like to get some clarity on the molecule that was banned on 31st December 2085 — I’m referring to nimesulide. So how is that going to affect our… up to 100 milligrams. How will it affect our revenue going forward? On that point.

Vishwa Savla executive
#81

Yes, sir. Okay. Harish bhai, can you—yeah. So essentially, that recent restriction applied to nimucilide above 100 milligrams. And normally in India, every formulation of this product that we sell falls below 100 milligrams. Therefore, where demand is concerned, we aren't impacted. Those are meant for very high doses, which in fact only two or three, four companies were manufacturing. So our entire customer base sits inside that range, and thus there's no issue with demand for that molecule right now.

Shashi Ranjan analyst
#82

I just want to clarify that point. Could you put a number on the revenue we bring in from Nimusilide on the formulations below 100 milligrams?

Vishwa Savla executive
#83

The bulk of what we sell in Nimiculide is.

Shashi Ranjan analyst
#84

No—what I want is the revenue figure, sir. That number isn’t available at the moment. We can probably obtain it and follow up with you afterward. Thank you. Then, if you’ll permit me, my next question is: what is capacity utilization at present in API and FDS? Is it 30 and 50 once more, the same figures you gave a short time ago?

Vishwa Savla executive
#85

Right. So, as I mentioned during the opening remarks, in this particular quarter — even compared with our capacity utilization for the first two quarters of the current year, that is H1FY26 — we were down by almost 4 to 5% from what we achieved in those first two quarters. And we also pointed out the reasons behind that. Most of those reasons are now behind us. So looking ahead, we don't expect disruptions of that kind in the quarters to come. At least.

Shashi Ranjan analyst
#86

Turning to the final question, could you share the gross margin and the revenue we're seeing from CDMO, and will we be using the backward integrated products within the CDMO products we're currently operating?

Vishwa Savla executive
#87

No, not exactly. We're backward integrated, so whatever products we're making in—specifically, you could call it CDMO or CMO—those are fine. With this chlorosulfonation chemistry, we're already backward integrated there. So all of these are derivatives of that chlorosulfonic chemistry. In that sense, we're already backward integrated. It can't be quantified as a percentage, because right now it isn't that big for us. That's why we still group it under the spectrum segment as of now.

Shashi Ranjan analyst
#88

All right, so moving to the final question — the European approval we received for the product in buddy, does that pertain to oncology or something else? Can you — would you like to take that one?

Vishwa Savla executive
#89

Yes. That applies to the general tablet and capsule facility along with the oncology facility. So both sites were inspected together, and at this point we hold EU GMP approval for the oncology site as well as the general oral solid dosage site.

Shashi Ranjan analyst
#90

Appreciate it a lot. That's everything I had. I’ll hop back in.

Vishwa Savla executive
#91

Appreciate it.

operator operator
#92

Thanks. Our next question comes from Vishal at Systematics. Please go ahead.

Vishal Manchanda analyst
#93

Yes, hello, and thanks. Could you tell us the overall investment we'll be putting into the oncology business, including the dossier development cost?

Vishwa Savla executive
#94

Right. So the capital expenditure on the facility across both phases — what we did at the outset plus the brownfield expansion we currently have underway — comes to roughly 50 crores, and on the product development and regulatory side it would again be around 50 to 60 crores each year over the coming 3 years.

Vishal Manchanda analyst
#95

All right, that's the amount we're putting into product development, broadly speaking. 200 crores, correct? Including.

Vishwa Savla executive
#96

Right, 200 crores over a period of time. Yes, that includes both capex and product development plus regulatory. And is it fair to expect an asset turn of 1.5 here?

Vishal Manchanda analyst
#97

Yeah, we can expect roughly 1.5 to 1.75 of capacity. And for the dossiers we're filing, do we already have partners in place?

Vishwa Savla executive
#98

Right, typically in most territories we already have B2B partners in place before we file.

Vishal Manchanda analyst
#99

Our capacity is around 300 million pills, specifically for oncology.

Vishwa Savla executive
#100

Yeah, that's correct — 300 million. All right. All right. Then just one question about salicylic acid. Could you give us some sense of why we sort of landed on salicylic as the import-substitute option, when there were so many others — you could equally have picked a backward-integration project for metformin. So what made us go with salicylic acid?

Vishal Manchanda analyst
#101

Right, yeah. So we looked at how salicylic acid pricing had moved over the five to six years before we picked that product. At that point, nobody else was making it. The technology we'd developed, you know, delivered a very strong profit margin. The IRR on that product was above 20%. But what happened was, once we came into the market, that's when China began pushing prices down, probably. Because they were afraid a new entrant would arrive. So if they hold prices at rock bottom during that initial stretch, that'll discourage us from proceeding, you know, from moving forward with salicylic. So we see that as a, you could call it, an entry barrier, or a temporary one, that they're attempting to put up. Fortunately this also turns into an anti-dumping case, since they slashed prices when the Indian manufacturer entered. So if we receive that benefit even for, you know, the first few years, we're confident we'll turn it around. Because the same thing happened with Metro and ciprofloxacin as well in the past — we got anti-dumping duties for four or five years, and by the next round, when it came, we were so profitable that we didn't qualify for anti-dump duty.

Vishal Manchanda analyst
#102

We believe a turnaround is coming. And the key point is that salicylic acid also creates a significant chance for us to move into the cosmetic and healthcare segment. Of business, rather than limiting ourselves to atrium. That's one more benefit we. Gain by means of salicylic acid. It's a base product used to make salicylates that go into the flavor and fragrances industry. So we'll produce downstream products from this.

Vishwa Savla executive
#103

The way things stand at the moment, we're being compared to do. We've already built the technology for that. We've also completed piloting for the downstream products. So we're bringing out salicylate. Block as well quite recently, within a quarter or two. So let's see how that works out.

Shashi Ranjan analyst
#104

Sir, did you file a request for anti-dumping duty?

Vishal Manchanda analyst
#105

So like I mentioned before, we hadn’t qualified at that point, but at this stage I believe it’ll be around April or so. Right. We’re going to be filing for the. Yeah.

Vishwa Savla executive
#106

Yeah, so the filing will likely happen around April — probably April.

Shashi Ranjan analyst
#107

Alright, sir. Alright. Thanks. Thanks a lot.

Vishwa Savla executive
#108

I appreciate that.

operator operator
#109

Thanks. Ladies and gentlemen. Because of time constraints, that was the final question for today. I'll now hand the conference back to management. Closing comments.

Vishwa Savla executive
#110

Thank you. The strategic investments and initiatives we've put in place over the past year are starting to come together, setting the stage for a new phase of growth for RT Drugs. We expect a more pronounced impact on our financial performance in the quarters ahead, as capacity utilization scales up and our improved product mix starts to drive higher profitability. We appreciate your continued support and trust in Arthur Trust. If you have any further questions, please reach out to sga, our investor relations advisors. Thank you, and have a nice day.

operator operator
#111

Thank you. That brings us to the end of this conference on behalf of RT Drugs limited. We appreciate your participation, and at this point you’re welcome to disconnect your lines. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Aarti Drugs Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Aarti Drugs Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.